SAN DIEGO, May 2, 2012 /PRNewswire/ – Trovagene, Inc. (TROV.PK) announced today that the Company has initiated development of a diagnostic test to determine the presence of high risk Human Papilloma Virus (HPV) subtypes from urine specimens. The proprietary test (U.S. … Continue reading
LONDON (Reuters) – Using GlaxoSmithKline’s Cervarix vaccine to protect girls against the HPV virus that causes cervical cancer is so effective that health authorities could reduce the need for later cervical screening, scientists said on Wednesday. Researchers from Finland and … Continue reading
Using GlaxoSmithKline’s Cervarix vaccine to protect girls against the HPV virus that causes cervical cancer is so effective that health authorities could reduce the need for later cervical screening, scientists said on Wednesday. Researchers from Finland and the United States … Continue reading
LONDON (Reuters) – Using GlaxoSmithKline’s Cervarix vaccine to protect girls against the HPV virus that causes cervical cancer is so effective that health authorities could reduce the need for later cervical screening, scientists said on Wednesday. Researchers from Finland and … Continue reading
WASHINGTON (Reuters) – A U.S. government-backed medical panel on Wednesday took a cautious view of a new generation of cervical cancer tests, discouraging women under the age of 30 to screen for human papillomavirus as a way to prevent cancer. … Continue reading
A key federal advisory panel on Wednesday said it will not endorse HPV screening for cervical cancer and favors giving Pap tests only every three years in women between ages 21 and 65. The U.S. Preventive Services Task Force said … Continue reading
WEDNESDAY, Oct. 19 (HealthDay News) — Three leading U.S. cancer groups have proposed new guidelines for cervical cancer testing for women, including when to start screening for sexually active young women, extending intervals between screenings and in some cases, supplementing … Continue reading